Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 215650, 10 pages
http://dx.doi.org/10.1155/2014/215650
Research Article

New Acquisition Protocol of 18F-Choline PET/CT in Prostate Cancer Patients: Review of the Literature about Methodology and Proposal of Standardization

Department of Nuclear Medicine, PET/CT Centre, “Santa Maria della Misericordia” Hospital, Via Tre Martiri 140, 45100 Rovigo, Italy

Received 28 February 2014; Revised 3 June 2014; Accepted 9 June 2014; Published 10 July 2014

Academic Editor: Giampiero Giovacchini

Copyright © 2014 Sotirios Chondrogiannis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Picchio, C. Messa, C. Landoni et al., “Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography,” Journal of Urology, vol. 169, no. 4, pp. 1337–1340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. J. Krause, M. Souvatzoglou, M. Tuncel et al., “The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Bertagna, M. Abuhilal, G. Bosio et al., “Role of 11C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation,” Japanese Journal of Radiology, vol. 29, no. 6, pp. 394–404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Cimitan, R. Bortolus, S. Morassut et al., “[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 12, pp. 1387–1398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Pelosi, V. Arena, A. Skanjeti et al., “Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer,” Radiologia Medica, vol. 113, no. 6, pp. 895–904, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Marzola, S. Chondrogiannis, A. Ferretti et al., “Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution,” Clinical Nuclear Medicine, vol. 38, no. 1, pp. e26–e32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. C. H. Steiner, H. Vees, H. Zaidi et al., “Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence,” NuklearMedizin, vol. 48, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Evangelista, F. Zattoni, A. Guttilla, G. Saladini, P. M. Colletti, and D. Rubello, “Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis,” Clinical Nuclear Medicine, vol. 38, no. 5, pp. 305–314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. J. Krause, M. Souvatzoglou, and U. Treiber, “Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 4, pp. 427–435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Kwee, H. Wei, I. Sesterhenn, D. Yun, and M. N. Coel, “Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET,” The Journal of Nuclear Medicine, vol. 47, no. 2, pp. 262–269, 2006. View at Google Scholar · View at Scopus
  12. M. Heinisch, A. Dirisamer, W. Loidl et al., “Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?” Molecular Imaging and Biology, vol. 8, no. 1, pp. 43–48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Vees, F. Buchegger, S. Albrecht et al., “18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy,” BJU International, vol. 99, no. 6, pp. 1415–1420, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Igerc, S. Kohlfürst, H. J. Gallowitsch et al., “The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 976–983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. B. Husarik, R. Miralbell, M. Dubs et al., “Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Beauregard, S. G. Williams, T. R. Degrado, P. Roselt, and R. J. Hicks, “Pilot comparison of 18F-fluorocholine and 18F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer,” Journal of Medical Imaging and Radiation Oncology, vol. 54, no. 4, pp. 325–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Hodolic, “Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma,” Radiology and Oncology, vol. 45, no. 1, pp. 17–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Soyka, M. A. Muster, D. T. Schmid et al., “Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 6, pp. 936–943, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Henninger, P. Vesco, D. Putzer et al., “[18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy—a preliminary study,” Nuclear Medicine Communications, vol. 33, no. 8, pp. 889–894, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. Poulsen, K. Bouchelouche, P. F. Høilund-Carlsen et al., “[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients,” BJU International, vol. 110, no. 11, pp. 1666–1671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Kwee, M. N. Coel, and J. Lim, “Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging,” Annals of Nuclear Medicine, vol. 26, no. 6, pp. 501–507, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. D. E. Oprea-Lager, A. D. Vincent, R. J. A. van Moorselaar et al., “Dual-phase PET-CT to differentiate [18F] Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer,” PLoS ONE, vol. 7, no. 10, Article ID e48430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Graute, N. Jansen, C. Übleis et al., “Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 2, pp. 271–282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kjölhede, G. Ahlgren, H. Almquist et al., “Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer,” BJU International, vol. 110, no. 10, pp. 1501–1506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Beheshti, S. Haim, R. Zakavi et al., “Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics,” Journal of Nuclear Medicine, vol. 54, no. 6, pp. 833–840, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Calabria, A. Chiaravalloti, and O. Schillaci, “18F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer,” Clinical Nuclear Medicine, vol. 39, no. 2, pp. 122–130, 2014. View at Google Scholar
  27. A. Afshar-Oromieh, C. M. Zechmann, A. Malcher et al., “Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 1, pp. 11–20, 2014. View at Publisher · View at Google Scholar
  28. F. Buchegger, V. Garibotto, T. Zilli et al., “First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 1, pp. 68–78, 2014. View at Publisher · View at Google Scholar
  29. B. Detti, S. Scoccianti, D. Franceschini et al., “Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 3, pp. 521–528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Hausmann, L. K. Bittencourt, U. I. Attenberger et al., “Diagnostic accuracy of 18F choline PET/CT using time-of-flight reconstruction algorithm in prostate cancer patients with biochemical recurrence,” Clinical Nuclear Medicine, vol. 39, no. 3, pp. e197–e201, 2014. View at Publisher · View at Google Scholar
  31. T. R. DeGrado, R. E. Coleman, S. Wang et al., “Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer,” Cancer Research, vol. 61, no. 1, pp. 110–117, 2001. View at Google Scholar · View at Scopus
  32. T. Hara, N. Kosaka, and H. Kishi, “Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging,” Journal of Nuclear Medicine, vol. 43, no. 2, pp. 187–199, 2002. View at Google Scholar · View at Scopus
  33. A. Massaro, A. Ferretti, C. Secchiero et al., “Optimising 18F-Choline PET/CT acquisition protocol in prostate cancer patients,” North American Journal of Medical Sciences, vol. 4, no. 9, pp. 416–420, 2012. View at Publisher · View at Google Scholar · View at Scopus